Haemonetics (NYSE: HAE) awards director 2,538 RSUs vesting on first anniversary

Rhea-AI Filing Summary

KROLL MARK W reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Mark W. Kroll reported an equity award of 2,538 restricted stock units (RSUs) granted under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one (1) share of common stock when vested. Following this award, his reported direct holdings are 27,295 common shares, including these RSUs.

Insider Trade Summary

Net Buyer: 2,538 shares

Net Buy 1 txn

Insider KROLL MARK W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	2,538	--	--

Holdings After Transaction: Common Stock — 27,295 shares (Direct)

Footnotes (2)

1. F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
2. F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSUs granted: 2,538 units Holdings after award: 27,295 shares Vesting schedule: 100% +1 more

4 metrics

RSUs granted 2,538 units Restricted stock units awarded to director Mark W. Kroll

Holdings after award 27,295 shares Reported direct common stock holdings following the RSU grant

Vesting schedule 100% RSUs vest 100% on the first anniversary of the grant date

RSU-to-share ratio 1 RSU : 1 share Each RSU represents a contingent right to receive one (1) share of common stock

Key Terms

restricted stock units ("RSUs"), contingent right, Long-Term Incentive Compensation Plan

3 terms

restricted stock units ("RSUs") financial

"The securities awarded are in the form of restricted stock units ("RSUs") issued"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one (1) share"

Long-Term Incentive Compensation Plan financial

"pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:58 PM Accepted by SEC EDGAR 07/28/2026 - 04:58 PM Learn about SEC filing dates

FAQ

What did Haemonetics (HAE) director Mark W. Kroll receive in this insider transaction?

Mark W. Kroll received an equity award of 2,538 restricted stock units (RSUs). The RSUs were granted under Haemonetics Corporation’s Amended and Restated 2019 Long-Term Incentive Compensation Plan and will vest 100% on the first anniversary of the grant date.

When do the 2,538 Haemonetics (HAE) RSUs granted to Mark W. Kroll vest?

The 2,538 RSUs granted to Mark W. Kroll vest 100% on the first anniversary of the grant date. Once vested, each RSU converts into one share of Haemonetics common stock, increasing his deliverable share ownership.

How many Haemonetics (HAE) shares does Mark W. Kroll hold after this award?

After the RSU award, Mark W. Kroll’s reported direct holdings are 27,295 common shares. This figure includes the newly granted RSUs, which represent contingent rights to receive shares when the units vest in full.

What does each Haemonetics (HAE) RSU granted to Mark W. Kroll represent?

Each RSU granted to Mark W. Kroll represents a contingent right to receive one (1) share of Haemonetics common stock. The shares become deliverable only after the RSUs vest, which occurs 100% on the first anniversary of the grant date.

Under which plan were the 2,538 Haemonetics (HAE) RSUs to Mark W. Kroll issued?

The 2,538 RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. This plan provides equity-based awards such as RSUs to align director and executive compensation with shareholder interests.

Was Mark W. Kroll’s Haemonetics (HAE) RSU grant made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox for this transaction was not selected. The reported award is a grant of RSUs, and no indication is given that it was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KROLL MARK W

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		A		2,538(1)	A	(2)	27,295	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Dr. Kroll	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)